Amgen Ventures and M Ventures returned to reinvest in Akili Interactive Labs, a developer of game-based treatments for cognitive conditions.

US-based digital medication developer Akili Interactive Labs completed a $55m series C round yesterday featuring Amgen Ventures and M Ventures, subsidiaries of pharmaceutical firms Amgen and Merck Group respectively.

Singaporean state-owned investment firm Temasek led the round, which included Baillie Gifford, Jazz Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies.

Founded by biopharmaceutical company PureTech Health, Akili is developing action video game-based treatments for conditions such as attention-deficit and hyperactivity disorder (ADHD), major depressive disorder, autism spectrum disorder…